News & Views | Published:

Antibodies in the breakdown lane

An engineered IgG induces degradation of endogenous IgG, providing a potential therapeutic approach to autoimmune disease.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Vaccaro, C. et al. Nat. Biotechnol. 23, 1283–1288 (2005).

  2. 2

    Junghans, R.P. Immunol. Res. 16, 29–57 (1997).

  3. 3

    Martin, W.L., West, A.P. Jr., Gan, L. & Bjorkman, P.J. Molec. Cell. 7, 867–877 (2001).

  4. 4

    Bitonti, A.J. et al. Proc. Natl. Acad. Sci. USA 101, 9763–9768 (2004).

  5. 5

    Hinton, P.R. et al. J. Biol. Chem. 279, 6213–6216 (2004).

  6. 6

    Akilesh, S. et al. J. Clin. Invest. 113, 1328–1333 (2004).

  7. 7

    Liu, Z. et al. J. Exp. Med. 186, 777–783 (1997).

  8. 8

    Jin, F. & Balthasar, J.P. Hum. Immunol. 66, 403–410 (2005).

  9. 9

    Dall' Acqua, W.F. et al. J. Immunol. 169, 5171–5180 (2002).

  10. 10

    Ghetie, V. et al. Nat. Biotechnol. 15, 637–640 (1997).

  11. 11

    Samuelsson, A., Towers, T.L. & Ravetch, J.V. Science 291, 484–486 (2001).

  12. 12

    Getman, K.E. & Balthasar, J.P. J. Pharm. Sci. 94, 718–729 (2005).

  13. 13

    Roopenian, D.C. et al. J. Immunol. 170, 3528–3533 (2003).

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Figure 1: FcRn normally protects IgG from degradation by diverting endogenous IgG from lysosomes.

Bob Crimi